Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | MEP1A | Q16819 | 1/20 | 0.30 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL838228 | 0.82 | PNMT (0.50) | CYP3A4MEN1KMT2A | |
| SCHEMBL2644246 | 0.77 | IDO1 (0.49) | CYP3A4MAPK1 | |
| SCHEMBL641851 | 0.76 | PKM (0.50) | CYP3A4MEN1KMT2A | |
| SCHEMBL837381 | 0.74 | P2RX7 (0.38) | CYP3A4MAPK1MEN1KMT2A | |
| SCHEMBL641776 | 0.74 | P2RX7 (0.40) | CYP3A4MAPK1MEN1KMT2A | |
| SCHEMBL836980 | 0.71 | IDO1 (0.47) | KMT2A | |
| SCHEMBL835822 | 0.71 | P2RX7 (0.38) | CYP3A4MEN1KMT2A | |
| SCHEMBL15862863 | 0.71 | DPP4 (0.50) | KMT2A | |
| SCHEMBL10391426 | 0.71 | CYP1A2 (0.45) | CYP3A4MEN1KMT2A | |
| SCHEMBL837827 | 0.69 | AKR1B1 (0.50) | CYP3A4MAPK1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143264-B2 | Xanthine derivatives as selective HM74A agonists | GLAXOSMITHKLINE LLC (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GLAXOSMITHKLINE LLC | 2011-10-20 | — | — | US | disclosed |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION | 2010-07-15 | — | — | US | disclosed |
| US-20100168122-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168122-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, XDH, GPR88 | CYP3A4 774/4885MAPK1 1748/4885MEN1 2432/4885 |
| US-20110257205-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | GPR84, GPR88, XDH | CYP3A4 947/4885MAPK1 2278/4885MEN1 2894/4885 |
| US-20100179128-A1 | XANTHINE DERIVATIVES AS SELECTIVE HM74A AGONISTS | XDH, GPR84, GPR88 | CYP3A4 938/4885MAPK1 1678/4885MEN1 2661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.